Cargando…
Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets
Streptococcus suis is an important swine pathogen responsible for economic losses to the swine industry worldwide. There is no effective commercial vaccine against S. suis. The use of autogenous (“bacterin”) vaccines to control S. suis outbreaks is a frequent preventive measure in the field, althoug...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527783/ https://www.ncbi.nlm.nih.gov/pubmed/34666827 http://dx.doi.org/10.1186/s13567-021-01004-x |
_version_ | 1784586138928807936 |
---|---|
author | Obradovic, Milan R. Corsaut, Lorelei Dolbec, Dominic Gottschalk, Marcelo Segura, Mariela |
author_facet | Obradovic, Milan R. Corsaut, Lorelei Dolbec, Dominic Gottschalk, Marcelo Segura, Mariela |
author_sort | Obradovic, Milan R. |
collection | PubMed |
description | Streptococcus suis is an important swine pathogen responsible for economic losses to the swine industry worldwide. There is no effective commercial vaccine against S. suis. The use of autogenous (“bacterin”) vaccines to control S. suis outbreaks is a frequent preventive measure in the field, although scientific data on immunogenicity and reduction in mortality and morbidity are scarce. The goal of our study is to experimentally evaluate the immunogenicity and protective efficacy against homologous challenge in weaned piglets of a S. suis serotype 2 bacterin-based vaccine formulated with six different commercial adjuvants (Alhydrogel®, Emulsigen®-D, Quil-A®, Montanide™ ISA 206 VG, Montanide™ ISA 61 VG, and Montanide™ ISA 201 VG). The vaccine formulated with Montanide™ ISA 61 VG induced a significant increase in anti-S. suis antibodies, including both IgG1 and IgG2 subclasses, protected against mortality and significantly reduced morbidity and severity of clinical signs. Vaccines formulated with Montanide ISA 206 VG or Montanide ISA 201 VG also induced a significant increase in anti-S. suis antibodies and showed partial protection and reduction of clinical signs severity. Vaccines formulated with Alhydrogel®, Emulsigen®-D, or Quil-A® induced a low and IgG1-shifted antibody response and failed to protect vaccinated piglets against a homologous challenge. In conclusion, the type of adjuvant used in the vaccine formulation significantly influenced the immune response and efficacy of the vaccine against a homologous challenge. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13567-021-01004-x. |
format | Online Article Text |
id | pubmed-8527783 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85277832021-10-25 Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets Obradovic, Milan R. Corsaut, Lorelei Dolbec, Dominic Gottschalk, Marcelo Segura, Mariela Vet Res Research Article Streptococcus suis is an important swine pathogen responsible for economic losses to the swine industry worldwide. There is no effective commercial vaccine against S. suis. The use of autogenous (“bacterin”) vaccines to control S. suis outbreaks is a frequent preventive measure in the field, although scientific data on immunogenicity and reduction in mortality and morbidity are scarce. The goal of our study is to experimentally evaluate the immunogenicity and protective efficacy against homologous challenge in weaned piglets of a S. suis serotype 2 bacterin-based vaccine formulated with six different commercial adjuvants (Alhydrogel®, Emulsigen®-D, Quil-A®, Montanide™ ISA 206 VG, Montanide™ ISA 61 VG, and Montanide™ ISA 201 VG). The vaccine formulated with Montanide™ ISA 61 VG induced a significant increase in anti-S. suis antibodies, including both IgG1 and IgG2 subclasses, protected against mortality and significantly reduced morbidity and severity of clinical signs. Vaccines formulated with Montanide ISA 206 VG or Montanide ISA 201 VG also induced a significant increase in anti-S. suis antibodies and showed partial protection and reduction of clinical signs severity. Vaccines formulated with Alhydrogel®, Emulsigen®-D, or Quil-A® induced a low and IgG1-shifted antibody response and failed to protect vaccinated piglets against a homologous challenge. In conclusion, the type of adjuvant used in the vaccine formulation significantly influenced the immune response and efficacy of the vaccine against a homologous challenge. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13567-021-01004-x. BioMed Central 2021-10-19 2021 /pmc/articles/PMC8527783/ /pubmed/34666827 http://dx.doi.org/10.1186/s13567-021-01004-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Obradovic, Milan R. Corsaut, Lorelei Dolbec, Dominic Gottschalk, Marcelo Segura, Mariela Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
title | Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
title_full | Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
title_fullStr | Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
title_full_unstemmed | Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
title_short | Experimental evaluation of protection and immunogenicity of Streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
title_sort | experimental evaluation of protection and immunogenicity of streptococcus suis bacterin-based vaccines formulated with different commercial adjuvants in weaned piglets |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527783/ https://www.ncbi.nlm.nih.gov/pubmed/34666827 http://dx.doi.org/10.1186/s13567-021-01004-x |
work_keys_str_mv | AT obradovicmilanr experimentalevaluationofprotectionandimmunogenicityofstreptococcussuisbacterinbasedvaccinesformulatedwithdifferentcommercialadjuvantsinweanedpiglets AT corsautlorelei experimentalevaluationofprotectionandimmunogenicityofstreptococcussuisbacterinbasedvaccinesformulatedwithdifferentcommercialadjuvantsinweanedpiglets AT dolbecdominic experimentalevaluationofprotectionandimmunogenicityofstreptococcussuisbacterinbasedvaccinesformulatedwithdifferentcommercialadjuvantsinweanedpiglets AT gottschalkmarcelo experimentalevaluationofprotectionandimmunogenicityofstreptococcussuisbacterinbasedvaccinesformulatedwithdifferentcommercialadjuvantsinweanedpiglets AT seguramariela experimentalevaluationofprotectionandimmunogenicityofstreptococcussuisbacterinbasedvaccinesformulatedwithdifferentcommercialadjuvantsinweanedpiglets |